Skip to main content

Table 7 Treatment-related AEs

From: Utility and predictive value of the CRAFITY score in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus tyrosine kinase inhibitors and PD-1 inhibitor

Items

 

CRAFITY-low (n = 25)

CRAFITY-intermediate (n = 29)

CRAFITY-high (n = 16)

P Value

Total

Any

23 (92.00%)

25 (86.20%)

14 (87.50%)

0.790

 

Grade ≥ 3

4 (16.00%)

3 (10.34%)

2 (12.50%)

0.824

TACE attributed

     

Abdominal pain

Any

20 (80.00%)

22 (75.86%)

11 (68.75%)

0.714

 

Grade ≥ 3

0 (00.00%)

0 (00.00%)

0 (00.00%)

-

Fever

Any

21 (84.00%)

23 (79.31%)

13 (81.25%)

0.906

 

Grade ≥ 3

0 (00.00%)

0 (00.00%)

0 (00.00%)

-

Nausea/vomiting

Any

17 (68.00%)

21 (72.41%)

12 (75.00%)

0.878

 

Grade ≥ 3

0 (00.00%)

0 (00.00%)

0 (00.00%)

-

Transaminitis

Any

22 (88.00%)

25 (86.21%)

13 (81.25%)

0.829

 

Grade ≥ 3

0 (00.00%)

0 (00.00%)

0 (00.00%)

-

Systemic therapy attributed

     

Fatigue

Any

6 (24.00%)

6 (20.69%)

8 (50.00%)

0.093

 

Grade ≥ 3

0 (00.00%)

0 (00.00%)

0 (00.00%)

-

Secondary Hypertension

Any

10 (40.00%)

8 (27.58%)

5 (31.25%)

0.618

 

Grade ≥ 3

4 (16.00%)

3 (10.34%)

2 (12.50%)

0.824

Hand-foot syndrome

Any

7 (28.00%)

5 (17.24%)

5 (31.25%)

0.495

 

Grade ≥ 3

0 (00.00%)

0 (00.00%)

0 (00.00%)

-

Diarrhea/colitis

Any

2 (8.00%)

1(3.44%)

0 (00.00%)

0.447

 

Grade ≥ 3

0 (00.00%)

0 (00.00%)

0 (00.00%)

-

Protein urea

Any

4 (16.00%)

4 (13.79%)

8 (50.00%)

0.012

 

Grade ≥ 3

0 (00.00%)

0 (00.00%)

1 (6.25%)

0.180

Hypothyroidism

Any

1 (4.00%)

1 (3.45%)

0 (00.00%)

0.731

 

Grade ≥ 3

0 (00.00%)

0 (00.00%)

0 (00.00%)

-

Constipation

Any

3 (12.00%)

5 (6.89%)

3 (18.75%)

0.809

 

Grade ≥ 3

0 (00.00%)

0 (00.00%)

0 (00.00%)

-

Decreased appetite

Any

8 (32.00%)

11 (37.93%)

9 (75.00%)

0.289

 

Grade ≥ 3

0 (00.00%)

0 (00.00%)

0 (00.00%)

-

Hypothyroidism

Any

0 (00.00%)

1 (3.45%)

0 (00.00%)

0.488

 

Grade ≥ 3

0 (00.00%)

0 (00.00%)

0 (00.00%)

-

Rash

Any

1 (4.00%)

2 (6.89%)

1 (6.25%)

0.895

 

Grade ≥ 3

0 (00.00%)

0 (00.00%)

0 (00.00%)

-

Gingival bleeding

Any

2 (8.00%)

2 (6.89%)

1 (6.25%)

0.975

 

Grade ≥ 3

0 (00.00%)

0 (00.00%)

0 (00.00%)

-

Insomnia

Any

1 (4.00%)

2 (6.89%)

1 (6.25%)

0.895

 

Grade ≥ 3

0 (00.00%)

0 (00.00%)

0 (00.00%)

-

Pneumonitis

Any

0 (00.00%)

1 (3.45%)

1 (6.25%)

0.488

 

Grade ≥ 3

0 (00.00%)

0 (00.00%)

0 (00.00%)

-

  1. AEs, adverse events; TACE, transarterial chemoembolization